Moderna's updated Spikevax shot includes 25 µg of spike protein mRNA from BA.4/BA.5 and 25 µg from the original strain of SARS-CoV-2, and has been authorised for the over-18s. It has also been ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

In the latest trading session, Moderna (MRNA) closed at $41.66, marking a +0.6% move from the previous day. The S&P 500 logs the best first week of a presidential term in four decades. Here are ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

Dr. Ashish Jha, head of the Biden administration’s Covid-19 task force, confirmed on Tuesday that the White House is monitoring “the rise of several subvariants” but the new booster shots ...

Making the world smarter, happier, and richer.